Adcendo is a biotechnology startup that specializes in the development of antibody-drug conjugates (ADCs), a type of cancer treatment that targets specific cancer cells. The company was founded in 2017 as a spin-off from the University of Copenhagen and Rigshospitalet. Its founders, Niels Behrendt, Lars Engelholm, and Christoffer Nielsen, have over 20 years of experience in cancer research and drug development.

Adcendo's primary focus is on the uPARAP receptor, a molecule involved in cancer development and metastasis. The founders have demonstrated that ADCs targeting this receptor can effectively treat cancer in preclinical models. This discovery led to the creation of Adcendo, which aims to further investigate and develop these findings into viable cancer treatments.

The company operates in the biotechnology and pharmaceutical market, serving clients such as hospitals, healthcare providers, and potentially, cancer patients. Its business model revolves around the research, development, and commercialization of its ADCs. Revenue is generated through the successful development and sale of these cancer treatments, as well as through partnerships with other biotech and pharmaceutical companies.

In 2021, Adcendo secured 51 million EUR in a series A investment round, which was extended by an additional 31 million EUR in 2023. This funding, provided by an international syndicate of life science and biotech investors, will support the company's ongoing research and development efforts.

Keywords: Biotechnology, Antibody-Drug Conjugates (ADCs), Cancer Treatment, uPARAP Receptor, Research and Development, University of Copenhagen, Rigshospitalet, Series A Funding, Biotech Investors, Pharmaceutical Market.